United States Patent and Trademark Office

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024

Retrieved on: 
Friday, August 11, 2023
Biotechnology, General Health, Pharmaceutical, Health, Patent, Air force academy, Partnership, PRV, Drug development, Technology transfer, U.S. Department of Defense Strategy for Operating in Cyberspace, Pharming, Bank statement, United States Patent and Trademark Office, International Accounting Standards Board, New Drug Application, Defense Threat Reduction Agency, NDA, Infection, United States Air Force Academy, Research, Government, Metronidazole, DOD, Investigational New Drug, Non-governmental organization, Indian stock exchange, PDUFA, The Last of Us Part I, TSX, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Therapy, Food, Pharmaceutical industry, Security (finance), USAFA, Tularemia

Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the first quarter of its fiscal year 2024, which ended on June 30, 2023.

Key Points: 
  • Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the first quarter of its fiscal year 2024, which ended on June 30, 2023.
  • These achievements are expected to position us with the required resources to continue to make progress in advancing our infectious disease assets."
  • On May 5, 2023, Appili executed an initial cooperative agreement with USAFA the previously announced funding of the ATI-1701 program.
  • This initial funding, in the amount of US$7.3 million, will be used to kick-off ATI-1701 early-stage development and regulatory activities.

HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Friday, August 11, 2023
1836 U.S. Patent Office fire, Pancreatic cancer, Patent, Carcinoma, Insurance, Prejudice, Loss, Masonic Cancer Center, University, ICI, TGF, University of Minnesota, Hepatocellular carcinoma, JAMS, Neoplasm, Bank statement, United States Patent and Trademark Office, Clinical trial, Cancer, G&A, Inflammation, Cell, Sale, District court, Lymph, Colorectal cancer, Melanoma, Court, R, United States Department of the Treasury, Research, Ovarian cancer, Credit, Notifiable disease, IND, Douglas v. U.S. District Court ex rel Talk America, Tumor microenvironment, Immunosuppression, Stomach, Breast cancer, Pharmaceutical industry, Bank, Cryptocurrency

MIRAMAR, Fla., Aug. 11, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2023.

Key Points: 
  • MIRAMAR, Fla., Aug. 11, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2023.
  • On August 10, 2023 the Company obtained construction permits required to begin the buildout of its new headquarters.
  • Second Quarter 2023 Financial Results:
    Revenues: Revenues for the quarter ended June 30, 2022 and 2023 were $454,000 and $622,807, respectively.
  • Net loss: Net loss for the quarter ended June 30, 2022 and 2023 was $3.5 million and $4.3 million, respectively, an increase of $793,859, or 23%.

HeartBeam Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 10, 2023
Data Management, Biometrics, IOT (Internet of Things), Apps, Applications, Medical Devices, Technology, Artificial Intelligence, Health Technology, Cardiology, Biotechnology, Wearables, Mobile Technology, Health, Patent, Common stock, Boston Scientific, Intellectual property, United States Patent and Trademark Office, Splenic infarction, Innovation, Doctor of Philosophy, Sale, DO, Coronary occlusion, Investment, Version 1, Webcast, CFO, AI, Regulatory affairs, Research, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Medical device, Management, Video game, Cryptocurrency

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, has reported its financial and operational results for the second quarter ended June 30, 2023.

Key Points: 
  • HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, has reported its financial and operational results for the second quarter ended June 30, 2023.
  • Research and development expenses for the second quarter of 2023 were $1.5 million, compared to $1.7 million for the second quarter of 2022.
  • General and administrative expenses for the second quarter of 2023 were $1.8 million compared to $1.8 million for the second quarter of 2022.
  • Net loss for the second quarter of 2023 was $3.2 million, compared to a net loss of $3.5 million for the second quarter of 2022.

Ecogensus Announces Groundbreaking Reinforced Sustainable Composite Material

Retrieved on: 
Thursday, August 10, 2023
Science, DOR, United States Patent and Trademark Office, Research, Recycling

U.S. Patent Office Granted the Composition Patent on July 4th, 2023

Key Points: 
  • U.S. Patent Office Granted the Composition Patent on July 4th, 2023
    HOUSTON, Aug. 10, 2023 /PRNewswire/ -- Ecogensus today unveiled its new structurally reinforced, waste-derived lumber innovation, a significant development towards liberating waste-derived substances for use in a broader set of sustainable building material applications.
  • The structurally reinforced composite adds secondary strength-enhancing polymers, such as in the form of rods.
  • Ecogensus is conducting further research in methods of cross-linking polymers, such that the EGS-6™ composite material becomes bonded to embedded polymer matrices or other solid structures.
  • "With this new development, we believe Ecogensus is placing itself at the intersection of materials science and sustainable resources," said the inventor and CEO/CTO Bjørnulf Østvik.

Ecogensus Announces Groundbreaking Reinforced Sustainable Composite Material

Retrieved on: 
Thursday, August 10, 2023
Science, DOR, United States Patent and Trademark Office, Research, Recycling

U.S. Patent Office Granted the Composition Patent on July 4th, 2023

Key Points: 
  • U.S. Patent Office Granted the Composition Patent on July 4th, 2023
    HOUSTON, Aug. 10, 2023 /PRNewswire/ -- Ecogensus today unveiled its new structurally reinforced, waste-derived lumber innovation, a significant development towards liberating waste-derived substances for use in a broader set of sustainable building material applications.
  • The structurally reinforced composite adds secondary strength-enhancing polymers, such as in the form of rods.
  • Ecogensus is conducting further research in methods of cross-linking polymers, such that the EGS-6™ composite material becomes bonded to embedded polymer matrices or other solid structures.
  • "With this new development, we believe Ecogensus is placing itself at the intersection of materials science and sustainable resources," said the inventor and CEO/CTO Bjørnulf Østvik.

Virpax Pharmaceuticals Files Provisional Patent Application for NSAID Formulation and Method

Retrieved on: 
Thursday, August 10, 2023
Surgery, Medical Devices, Infectious Diseases, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Patent, Central nervous system, Diclofenac, United States Patent and Trademark Office, CNS, Pain, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Post-traumatic stress disorder, OTC, Pain management, Gel, Hand, Osteoarthritis, IND, Skin, Pharmaceutical industry

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it has filed a new provisional patent application with the United States Patent and Trademark Office (‘USPTO’) entitled “NSAID Formulation and Method” related to its Epoladerm™product candidate.

Key Points: 
  • Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it has filed a new provisional patent application with the United States Patent and Trademark Office (‘USPTO’) entitled “NSAID Formulation and Method” related to its Epoladerm™product candidate.
  • Epoladerm is an over-the counter (OTC) diclofenac topical spray film that Virpax is developing for pain associated with Osteoarthritis.
  • Epoladerm is designed to be less messy than gels or creams which are applied by hand and which may contaminate public water supplies with the active pharmaceutical ingredients the gels or creams carry.
  • “We have completed our IND enabling trials for Epoladerm and are pleased to file this patent application that we expect will expand our protection and increase the patent life for this novel formulation,” stated Anthony P. Mack , Chairman and CEO of Virpax.

Dstillery Announces New Patent Related to its Groundbreaking ID-free® Ad Targeting Technology, its 19th Patent Overall

Retrieved on: 
Thursday, August 10, 2023
Patent, United States Patent and Trademark Office, ChatGPT, Privacy, Publication, Machine learning, AI, Data science, Sales

NEW YORK, Aug. 10, 2023 /PRNewswire/ -- Dstillery , the leading AI ad targeting company, announced that it has been issued its 19th paten t* by the United States Patent and Trademark Office (USPTO).

Key Points: 
  • NEW YORK, Aug. 10, 2023 /PRNewswire/ -- Dstillery , the leading AI ad targeting company, announced that it has been issued its 19th paten t* by the United States Patent and Trademark Office (USPTO).
  • The patent expands on the company's existing patent protection related to ID-free® technology by granting additional protection for its unique machine learning capabilities.
  • The result is privacy-safe behavioral targeting that reaches 100% of ad impressions and can be used to power a range of Dstillery targeting products.
  • We've found this view has broad implications for ad targeting both today and in a data-constrained future," said Melinda Han Williams, Chief Data Scientist at Dstillery.

Lightbridge Receives Notice of Allowance for a Pivotal Manufacturing Method Patent in the United States for its Metallic Fuel Rods

Retrieved on: 
Thursday, August 10, 2023
Patent, ZR, Engineering, Idaho National Laboratory, United States Patent and Trademark Office, Uranium, LTBR, Zirconium, INL, Extrusion, Thanasis Lightbridge

RESTON, Va., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Lightbridge Corporation (Nasdaq: LTBR), an advanced nuclear fuel technology company, announced that it received a Notice of Allowance for a crucial divisional patent from the United States Patent and Trademark Office related to a method of manufacturing Lighbridge’s multi-lobe helically twisted metallic fuel rods via the casting route, which is the Company’s preferred method of forming a fuel core billet prior to co-extrusing an entire billet assembly (i.e., fuel core billet together with a central displacer wire and a zirconium alloy cladding canister) into a complete fuel rod.

Key Points: 
  • RESTON, Va., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Lightbridge Corporation (Nasdaq: LTBR), an advanced nuclear fuel technology company, announced that it received a Notice of Allowance for a crucial divisional patent from the United States Patent and Trademark Office related to a method of manufacturing Lighbridge’s multi-lobe helically twisted metallic fuel rods via the casting route, which is the Company’s preferred method of forming a fuel core billet prior to co-extrusing an entire billet assembly (i.e., fuel core billet together with a central displacer wire and a zirconium alloy cladding canister) into a complete fuel rod.
  • Scott Holcombe, Vice President of Engineering at Lightbridge, stated, “This new U.S. patent coincides with our ongoing work at Idaho National Laboratory (INL) where we have recently performed initial castings using depleted uranium (U) and zirconium (Zr) to produce U-Zr fuel alloy ingots, which are currently undergoing characterization.
  • Our next steps are to scale up the ingot size to form fuel core billets suitable for extrusion, and then to conduct initial extrusions.”
    Seth Grae, President & Chief Executive Officer of Lightbridge, commented, “This is an important expansion of Lightbridge’s intellectual property around the manufacturing process for our patented metallic fuel rods.
  • This accomplishment underscores our dedication to technological leadership in advanced nuclear technologies, while strengthening our intellectual property protection in the United States, which is essential to our efforts in commercializing Lightbridge Fuel™.”

Optinose Reports Second Quarter 2023 Financial Results and Operational Updates

Retrieved on: 
Thursday, August 10, 2023
ENT, Patent, Exhalation delivery system, SG, Ear, Conference call, OPTN, General Administration of Press and Publication, Telephone, Prescription Drug User Fee Act, GAAP, Research, Nose, Orange Book, United States Patent and Trademark Office, Sinusitis, Patient, Approved Drug Products with Therapeutic Equivalence Evaluations, Fluticasone, PDUFA, Webcast, FDA, MPH, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Cryptocurrency, MD, Conference

YARDLEY, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended June 30, 2023, and provided operational updates.

Key Points: 
  • Conference call and webcast to be held today at 8:00 a.m. Eastern Time
    YARDLEY, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended June 30, 2023, and provided operational updates.
  • “We are pleased with the progress we made in the second quarter of 2023 towards our strategic objectives,” stated CEO Ramy Mahmoud, MD, MPH.
  • “That means we are outperforming our initial expectations for full year 2023 XHANCE net revenues while operating far more efficiently.
  • Members of the Company’s leadership team will host a conference call and presentation to discuss financial results and corporate updates beginning at 8:00 a.m. Eastern Time today.

Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, August 8, 2023
Janus, Patent, PDE4, SG, Marketing, Hair, United States Patent and Trademark Office, Food, New Drug Application, JAK1, Food and Drug Administration, NDA, Prescription, Atopic dermatitis, Pharmacy, Inflammation, Scalp, Psoriasis, Alopecia areata, Martin PBM Mariner, Dermatitis, Shanda, Patient, Physician, Great Places, 100 Best Workplaces in Europe, Webcast, Pivotal, Growth, Ageing, R, Research, FDA, Video game, Health care, Cryptocurrency, Fine chemical, Pharmaceutical industry, Cosmetics, Vaccine, Clothing

The Company anticipates submitting an sNDA to the FDA for ages 6 and above late in the third quarter or early in the fourth quarter of 2023.

Key Points: 
  • The Company anticipates submitting an sNDA to the FDA for ages 6 and above late in the third quarter or early in the fourth quarter of 2023.
  • The first subject in the alopecia areata cohort enrolled in the second quarter of 2023.
  • In July 2023, Great Place To Work® and Fortune magazine named the Company to the Best Workplaces for Millennials™ list for 2023.
  • Arcutis management will host a conference call and webcast today at 4:30pm ET to discuss the financial results for the quarter and provide a business update.